Roux-en-Y gastric bypass (RYGB) characteristically enhances postprandial levels of glucagon-like peptide 1 (GLP-1), a mechanism that contributes to its profound glucose-lowering effects. This enhancement is thought to be triggered by bypass of food to the distal small intestine with higher densities of neuroendocrine L-cells. We hypothesized that if this is the predominant mechanism behind the enhanced secretion of GLP-1, a longer intestinal bypass would potentiate the postprandial peak in GLP-1, translating into higher insulin secretion and, thus, additional improvements in glucose tolerance. To investigate this, we conducted a mechanistic study comparing two variants of RYGB that differ in the length of intestinal bypass.
RESEARCH DESIGN AND METHODSA total of 53 patients with type 2 diabetes (T2D) and obesity were randomized to either standard limb RYGB (50-cm biliopancreatic limb) or long limb RYGB (150-cm biliopancreatic limb). They underwent measurements of GLP-1 and insulin secretion following a mixed meal and insulin sensitivity using euglycemic hyperinsulinemic clamps at baseline and 2 weeks and at 20% weight loss after surgery.
RESULTSBoth groups exhibited enhancement in postprandial GLP-1 secretion and improvements in glycemia compared with baseline. There were no significant differences in postprandial peak concentrations of GLP-1, time to peak, insulin secretion, and insulin sensitivity.
CONCLUSIONSThe findings of this study demonstrate that lengthening of the intestinal bypass in RYGB does not affect GLP-1 secretion. Thus, the characteristic enhancement of GLP-1 response after RYGB might not depend on delivery of nutrients to more distal intestinal segments.Roux-en-Y gastric bypass (RYGB) is now a recognized and recommended treatment option for patients with type 2 diabetes (T2D) (1). RYGB can cause major and
Objective
<p>Roux-en-Y gastric bypass (RYGB) characteristically
enhances post-prandial levels of Glucagon-like peptide 1 (GLP-1), a mechanism that contributes
to its profound glucose-lowering effects. This enhancement is thought to be
triggered by bypass of food to the distal small intestine with higher densities
of neuroendocrine L-cells. We hypothesised that if this is the predominant
mechanism behind the enhanced secretion of GLP-1, a longer intestinal bypass
would potentiate the post-prandial peak in GLP-1, translating into higher
insulin secretion and thus additional improvements in glucose tolerance. To
investigate this, we conducted a mechanistic study comparing two variants of
RYGB that differ in the length of intestinal bypass.</p>
<p>Research
Design and Methods</p>
<p>Fifty-three
patients with type 2 diabetes and obesity were randomised to either ‘standard
limb’ RYGB (50cm biliopancreatic limb) or ‘long limb’ RYGB (150cm
biliopancreatic limb). They underwent measurements of GLP-1 and insulin
secretion following a mixed meal and insulin sensitivity using euglycaemic
hyperinsulinaemic clamps at baseline, 2 weeks and at 20% weight loss after
surgery.</p>
<p>Results</p>
<p>Both
groups exhibited enhancement in post-prandial GLP-1 secretion and improvements
in glycaemia compared to baseline. There were no significant differences in
post-prandial peak concentrations of GLP-1, time to peak, insulin secretion, and
insulin sensitivity. </p>
<p>Conclusion</p>
The findings of this study demonstrate
that lengthening of the intestinal bypass in RYGB does not affect GLP-1
secretion. Thus, the characteristic enhancement of GLP-1 response after RYGB might
not depend on delivery of nutrients to more distal intestinal segments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.